MMC vs RNAZ · P/E 22, rev $24.46B vs $5.1M cap
Marsh & McLennan Companies Inc (MMC) versus Transcode Therapeutics Inc (RNAZ) — a side-by-side from cached financials, not a winner call.
Marsh & McLennan Companies Inc (MMC) is a insurance brokers company listed on US.
Transcode Therapeutics Inc (RNAZ) is a biotechnology company listed on NASDAQ.
Latest reported MMC revenue for 2024-12-31 was $24.46B. Net income was $4.12B. Revenue was up 7.6% from 2023-12-31 to 2024-12-31. MMC currently screens at market cap $89.82B and trailing P/E 21.9.
RNAZ does not have a complete income-statement cache yet.
MMC currently screens at market cap $89.82B and trailing P/E 21.9. RNAZ currently screens at market cap $5.1M.
Not investment advice. Open the MMC and RNAZ stock pages for the full models.
Not investment advice.